Last reviewed · How we verify
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Research purposes: the research design in the late more than 2 lines TNBC prospective, multicenter, cohort study, respectively to observe Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) the efficacy and safety. Indications: Trop2 - ADC joint PD - 1 single or combined anti-angiogenesis drugs (macromolecular single bevacizumab or small molecules TKI resistance, for, as the default layered) treat above 2 late three negative breast cancer (TNBC).
Details
| Lead sponsor | Tianjin Medical University Cancer Institute and Hospital |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 138 |
| Start date | Fri Dec 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jun 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
Interventions
- Sacituzumab Govitecan combined with Toripalimab
- Sacituzumab govitecan combined with anti-angiogenesis
Countries
China